KTRA Kintara Pharma Earnings per share for the last twelve months

KTRA (Kintara Therapeutics Inc) - company brandmark

Kintara Therapeutics brings together scientists to combat rare forms of cancer within a flexible environment. The company's 12-month specific profit level on this GURU.Markets chart reflects the asset's dynamics, where -0.49 is recorded as the baseline value. The business is currently integrating its vaccine portfolio following a merger, relying on external CRO and CMO contractors to conduct testing.

KTRA (Kintara Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 11/17/2026

Kintara Pharma - analytical breakdowns and key metrics (KTRA)

- current quotes and average value forecast:
Basic company analysis:kintara.com (KTRA)
Mass-produced product of Kintara

Annual net earnings per share determine the portion of actual income attributable to a single security. The current trailing twelve-month EPS for Kintara Therapeutics (KTRA) demonstrates the efficiency of business capitalization without accounting for share dilution. The workforce reduction at Kintara Therapeutics (KTRA) to facilitate a merger with TuHURA directly impacts cost minimization, which is reflected in the dynamics of this metric. Trend analysis helps avoid overpaying for the asset. This metric confirms the company's actual ability to accumulate profit.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months